Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Patients With Non-Small Cell Lung Cancer

Inclusion Criteria:

Participants with non-small cell lung cancer with locally or advanced metastatic disease(Stage IIIB or IV at entry) not amenable to curative therapy and who have progressed after 1 line of chemotherapy
Measureable disease as defined by response evaluation criteria in solid tumors (RECIST) version 1.1
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
Must make available any existing tumor tissue from the primary biopsy
Participants with prior radiation may be eligible if they meet certain criteria
Adequate bone marrow reserve and organ functioning
Women must have a negative pregnancy test and must comply with a highly reliable contraceptive method during and for 6 months after the treatment period and must not be breastfeeding
Men must comply with a contraceptive regimen during and for 6 months after the treatment period

Exclusion Criteria:

Currently enrolled in or discontinued a clinical trial involving an investigational drug/device within the last 30 days. Participants may be permitted to enter treatment before the 30 day waiting period in special circumstances
Pregnant or breastfeeding
Serious concomitant systemic disorders that would compromise the safety of the participant or the participant's ability to complete the study
Second primary malignancy that could affect compliance with the protocol or interpretation of the study results
Known allergy or hypersensitivity to docetaxel, taxanes, LY2181308, oligonucleotides, or any component of the formulations
Participants with documented central nervous system or brain metastasis at the time of study entry
Pre-existing neuropathy equivalent to a common terminology criteria for adverse events(CTCAE)code greater than or equal to 2